1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079


Delayed Quote. Delayed Nasdaq - 05/25 04:00:00 pm
130.85 USD   -0.92%
05/25SECTOR UPDATE : Health Care Stocks End Near Unchanged
05/25SECTOR UPDATE : Health Care Stocks Falling This Afternoon
05/25SECTOR UPDATE : Health Care
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna CEO says data for Omicron-specific shot likely available in March

01/17/2022 | 08:59am EDT

Jan 17 (Reuters) - Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.

"The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps," Bancel said at the World Economic Forum's virtual Davos Agenda conference.

Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. (https://reut.rs/3FAeyya)

Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.

"Our goal is to be able to have a single annual booster so that we don't have compliance issues where people don't want to get two to three shots a winter."

Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.

Earlier in January, Moderna's CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.

However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union's drug regulator, which has expressed doubts about the need for a fourth booster dose.

Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.

"Giving boosters at different times, there is really no evidence that's going to hinder (immune response)."

Fauci said the goal should be to have a booster that induces a response against multiple potential variants. (Reporting by Mrinalika Roy in Bengaluru Editing by Mark Potter)

© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
MODERNA, INC. -0.92% 130.85 Delayed Quote.-48.48%
ON SEMICONDUCTOR CORPORATION 3.19% 56.24 Delayed Quote.-17.20%
All news about MODERNA, INC.
05/25SECTOR UPDATE : Health Care Stocks End Near Unchanged
05/25SECTOR UPDATE : Health Care Stocks Falling This Afternoon
05/25SECTOR UPDATE : Health Care
05/25Bioquebec - moderna manufacturing facility opening in montreal
05/25French health body backs new COVID vaccine booster campaign for this autumn
05/24Moderna's CEO Stephane Bancel to Exercise Shares, Intends to Donate Proceeds to Charity
05/24GLOBAL MARKETS LIVE : Broadcom, Airbnb, Roche, Toyota, Uber
05/24WALL STREET STOCK EXCHANGE : Snap cut the rally short
05/24Rubius Therapeutics Names Noubar Afeyan Chairman; Shares Rise Pre-Bell
05/24TRANSCRIPT : Moderna, Inc. Presents at UBS Global Healthcare Conference, May-24-2022 09:15..
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2022 22 069 M - -
Net income 2022 11 501 M - -
Net cash 2022 18 081 M - -
P/E ratio 2022 4,81x
Yield 2022 -
Capitalization 52 047 M 52 047 M -
EV / Sales 2022 1,54x
EV / Sales 2023 3,11x
Nbr of Employees 2 700
Free-Float 90,6%
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 130,85 $
Average target price 212,69 $
Spread / Average Target 62,5%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-48.48%52 047
LONZA GROUP AG-28.07%42 228
IQVIA HOLDINGS INC.-27.93%38 488
SEAGEN INC.-11.73%25 121
CELLTRION, INC.-22.73%16 687